LIFEVANTAGE CORP Other Comprehensive Income (Loss), Net of Tax (Deprecated 2012-01-31)
LIFEVANTAGE CORP (LFVN) reported Other Comprehensive Income (Loss), Net of Tax (Deprecated 2012-01-31) of $38.49 thousand for the 12-month period ending 2012-06-30, per its 10-K filed 2012-09-10.
Discontinued › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecrease · last filed 2012-09-10
- LIFEVANTAGE CORP other comprehensive income (loss), net of tax (deprecated 2012-01-31) for the quarter ending 2012-06-30 was $26.40K.
- LIFEVANTAGE CORP other comprehensive income (loss), net of tax (deprecated 2012-01-31) for the quarter ending 2012-03-31 was -$80.28K.
- LIFEVANTAGE CORP other comprehensive income (loss), net of tax (deprecated 2012-01-31) for the quarter ending 2011-12-31 was $8.77M, a 60.73% increase year-over-year.
- LIFEVANTAGE CORP other comprehensive income (loss), net of tax (deprecated 2012-01-31) for the quarter ending 2011-09-30 was $3.81M, a 443.37% increase year-over-year.
- LIFEVANTAGE CORP other comprehensive income (loss), net of tax (deprecated 2012-01-31) for fiscal 2012 was $38.49K.
- LIFEVANTAGE CORP other comprehensive income (loss), net of tax (deprecated 2012-01-31) for fiscal 2011 was -$27.91K.
| Period end | Other Comprehensive Income (Loss), Net of Tax (Deprecated 2012-01-31) 3 month | Other Comprehensive Income (Loss), Net of Tax (Deprecated 2012-01-31) 6 month | Other Comprehensive Income (Loss), Net of Tax (Deprecated 2012-01-31) 9 month | Other Comprehensive Income (Loss), Net of Tax (Deprecated 2012-01-31) 12 month |
|---|---|---|---|---|
| 2012-06-30 | $26.40K derived: 10-K 12 month − 10-Q 9 month · filed 2012-09-10 | -$53.88K derived: sum of 2 quarters · filed 2012-09-10 | $8.71M derived: sum of 3 quarters · filed 2012-09-10 | $38.49K 10-K · filed 2012-09-10 |
| 2012-03-31 | -$80.28K 10-Q · filed 2012-05-15 | $8.69M derived: sum of 2 quarters · filed 2012-05-15 | $12.09K 10-Q · filed 2012-05-15 | $12.49M derived: sum of 4 quarters · filed 2012-09-10 |
| 2011-12-31 | $8.77M 10-Q · filed 2012-02-14 | $12.58M 10-Q · filed 2012-02-14 | $12.57M derived: sum of 3 quarters · filed 2012-09-10 | $12.55M derived: sum of 4 quarters · filed 2012-09-10 |
| 2011-09-30 | $3.81M 10-Q · filed 2011-11-14 | $3.81M derived: sum of 2 quarters · filed 2012-09-10 | $3.79M derived: sum of 3 quarters · filed 2012-09-10 | $9.24M derived: sum of 4 quarters · filed 2012-09-10 |
| 2011-06-30 | -$3.08K derived: 10-K 12 month − 10-Q 9 month · filed 2012-09-10 | -$20.44K derived: sum of 2 quarters · filed 2012-09-10 | $5.43M derived: sum of 3 quarters · filed 2012-09-10 | -$27.91K 10-K · filed 2012-09-10 |
| 2011-03-31 | -$17.36K 10-Q · filed 2012-05-15 | $5.44M derived: sum of 2 quarters · filed 2012-05-15 | -$24.82K 10-Q · filed 2012-05-15 | |
| 2010-12-31 | $5.45M 10-Q · filed 2012-02-14 | $6.16M 10-Q · filed 2012-02-14 | ||
| 2010-09-30 | $700.87K 10-Q · filed 2011-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |